IMW 2019 | Using MRD as an endpoint in clinical trials

Hervé Avet-Loiseau

Hervé Avet-Loiseau, MD, PhD, Cancer Research Center of Toulouse, Toulouse, France, outlines the potential benefits of using (measurable residual disease) MRD as an
an endpoint in myeloma treatment at the International Myeloma Workshop (IMW) 2019, Boston, MA.

Share this video  
Similar topics